Why the study?
Does combined therapy with a beta1-adrenergic agonist, parasympathetic antagonist, and quinidine suppress VT/VF in an infant with malignant Brugada syndrome?
Does combined therapy with a beta1-adrenergic agonist, parasympathetic antagonist, and quinidine suppress VT/VF in an infant with malignant Brugada syndrome?
Combined therapy with a beta1-adrenergic agonist, parasympathetic antagonist, and quinidine may be an effective adjunctive therapy to suppress VT/VF in infants with malignant Brugada syndrome.
May support adjunctive use in refractory infant Brugada VT/VF; leaves open prospective validation.
We report a 6-month-old Japanese infant with a malignant form of Brugada syndrome, who had frequent episodes of ventricular fibrillation (VF) and nonsustained polymorphic ventricular tachycardia (VT). To the best of our knowledge, this infant is the youngest patient reported to have Brugada syndrome. Continuous infusion of a beta-adrenergic agonist and intravenous injection of a parasympathetic antagonist suppressed the electrical storm of polymorphic VT and VF. Combined oral administration of a beta1-adrenergic agonist, a parasympathetic antagonist, and quinidine has successfully suppressed recurrences of VT or VF for 6 months, and the combination may have the potential to decrease the incidence of VT or VF as an adjunctive therapy with prophylactic placement of an implantable cardioverter defibrillator.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: